Hyperglycaemic Metabolic Complications of Ischemic Brain : Current Therapeutics, Anti-Diabetics and Stem Cell Therapy
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Stroke is the leading cause of morbidity and mortality in diabetic patients. Diabetes alters the endothelial function and disrupts brain pathways, resulting in a variety of systemic metabolic complications. Diabetics not only have impaired neurotransmission, but also have progressive neurodegeneration, which leads to long-term neurological complications. Diabetes risk factors and physiology alter the frequency and severity of cardiovascular and cerebrovascular events, necessitating more hospitalizations. Stroke and diabetes have a mutually reinforcing relationship that worsens their outcomes. Diabetes has far-reaching systemic consequences for human physiology as a metabolic syndrome. As a result, diabetic stroke patients require dual-therapeutics with dual protection. Scientific researchers have made tremendous progress in diabetes-related stroke and its therapeutics over the last few decades. We have summarised diabetic brain and associated risk factors, co-morbidities, biomarkers, and hyperglycemia-associated neurovascular insult and cognitive demur. In addition to providing an overview of the effects of hyperglycaemia on brain physiology, this article aims to summarise the evidence from current glucose-lowering treatment, recent advances in stroke therapeutics as well as exploring stem cell therapy in the management of diabetes-associated stroke.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
CNS & neurological disorders drug targets - 22(2023), 6 vom: 09., Seite 832-856 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chavda, Vishal [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cerebrovascular stroke |
|---|
| Anmerkungen: |
Date Completed 19.05.2023 Date Revised 31.05.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1871527321666220609200852 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342138030 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342138030 | ||
| 003 | DE-627 | ||
| 005 | 20231226013412.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871527321666220609200852 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1140.xml |
| 035 | |a (DE-627)NLM342138030 | ||
| 035 | |a (NLM)35692163 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chavda, Vishal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hyperglycaemic Metabolic Complications of Ischemic Brain |b Current Therapeutics, Anti-Diabetics and Stem Cell Therapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.05.2023 | ||
| 500 | |a Date Revised 31.05.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Stroke is the leading cause of morbidity and mortality in diabetic patients. Diabetes alters the endothelial function and disrupts brain pathways, resulting in a variety of systemic metabolic complications. Diabetics not only have impaired neurotransmission, but also have progressive neurodegeneration, which leads to long-term neurological complications. Diabetes risk factors and physiology alter the frequency and severity of cardiovascular and cerebrovascular events, necessitating more hospitalizations. Stroke and diabetes have a mutually reinforcing relationship that worsens their outcomes. Diabetes has far-reaching systemic consequences for human physiology as a metabolic syndrome. As a result, diabetic stroke patients require dual-therapeutics with dual protection. Scientific researchers have made tremendous progress in diabetes-related stroke and its therapeutics over the last few decades. We have summarised diabetic brain and associated risk factors, co-morbidities, biomarkers, and hyperglycemia-associated neurovascular insult and cognitive demur. In addition to providing an overview of the effects of hyperglycaemia on brain physiology, this article aims to summarise the evidence from current glucose-lowering treatment, recent advances in stroke therapeutics as well as exploring stem cell therapy in the management of diabetes-associated stroke | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cerebrovascular stroke | |
| 650 | 4 | |a Hyperglycaemia | |
| 650 | 4 | |a diabetes | |
| 650 | 4 | |a ischemic insult | |
| 650 | 4 | |a neurodegeneration | |
| 650 | 4 | |a neurovascular complications | |
| 700 | 1 | |a Patel, Snehal |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t CNS & neurological disorders drug targets |d 2006 |g 22(2023), 6 vom: 09., Seite 832-856 |w (DE-627)NLM161975518 |x 1996-3181 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:6 |g day:09 |g pages:832-856 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871527321666220609200852 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 6 |b 09 |h 832-856 | ||